1-10 of 10
Jill Gilbert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-018: Hematology oncology COllaborative VIDeoconferencing (COVID) Learning Initiative: A multi-institutional trainee alliance to rapidly disseminate emerging SARS-CoV2 and cancer best practices

Richard L. Martin, Michael Grant, Rushad Patell, Shonali Middha, Jori May, Charles Bodine, Leo Reap, David Furfaro, Samuel Brusca, Jill Gilbert, Christine Lovly, Frances Collichio, Jennifer Green
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): PO-018.
https://doi.org/10.1158/1557-3265.COVID-19-PO-018
Published: 15 September 2020
View article titled, Abstract PO-018: Hematology oncology COllaborative VIDeoconferencing (COVID) Learning Initiative: A multi-institutional trainee alliance to rapidly disseminate emerging SARS-CoV2 and cancer best practices
Journal Articles

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Thomas J. Galloway, Lori J. Wirth, Alexander D. Colevas, Jill Gilbert, Julie E. Bauman, Nabil F. Saba, David Raben, Ranee Mehra, Anna W. Ma, Ruzanna Atoyan, Jing Wang, Barbara Burtness, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1566–1573.
https://doi.org/10.1158/1078-0432.CCR-14-2820
Published: 31 March 2015
View article titled, A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Open the PDF for A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Igor Puzanov, Colin R. Lindsay, Laura Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Rich Gedrich, Andrew Stephens, Emily Chan, T.R. Jeffry Evans
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (4): 701–711.
https://doi.org/10.1158/1078-0432.CCR-14-0303
Published: 16 February 2015
View article titled, A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, Shaunita A. Michael, Alain C. Mita, Monica M. Mita, Marilyn Mulay, Poornima Shubhakar, Min Zhu, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3414–3427.
https://doi.org/10.1158/1078-0432.CCR-11-3369
Published: 14 June 2012
View article titled, Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors
Open the PDF for Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

D. Neil Hayes, Amy S. Lucas, Tawee Tanvetyanon, Monika K. Krzyzanowska, Christine H. Chung, Barbara A. Murphy, Jill Gilbert, Ranee Mehra, Dominic T. Moore, Arif Sheikh, Janelle Hoskins, Michele C. Hayward, Ni Zhao, Wendi O'Connor, Karen E. Weck, Roger B. Cohen, Ezra E.W. Cohen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2056–2065.
https://doi.org/10.1158/1078-0432.CCR-11-0563
Published: 01 April 2012
View article titled, Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
Open the PDF for Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck

Jill Gilbert, Michelle A. Rudek, Michaela J. Higgins, Ming Zhao, Sara Bienvenu, Nancy Tsottles, Richard Wahl, Arlene Forastiere, Maura Gillison
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1735–1742.
https://doi.org/10.1158/1078-0432.CCR-11-2544
Published: 14 March 2012
View article titled, A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck
Open the PDF for A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck in another window
Journal Articles

A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors

Jianqing Lin, Jill Gilbert, Michelle A. Rudek, James A. Zwiebel, Steve Gore, Anchalee Jiemjit, Ming Zhao, Sharyn D. Baker, Richard F. Ambinder, James G. Herman, Ross C. Donehower, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6241–6249.
https://doi.org/10.1158/1078-0432.CCR-09-0567
Published: 30 September 2009
View article titled, A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
Open the PDF for A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation

Jill Gilbert, Steve D. Gore, James G. Herman, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4589–4596.
https://doi.org/10.1158/1078-0432.CCR-03-0297
Published: 21 July 2004
View article titled, The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation
Open the PDF for The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation in another window
Journal Articles

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule

Michael A. Carducci, Jill Gilbert, M. Katherine Bowling, Dennis Noe, Mario A. Eisenberger, Victoria Sinibaldi, Yelena Zabelina, Tian-ling Chen, Louise B. Grochow, Ross C. Donehower
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3047–3055.
Published: 01 October 2001
View article titled, A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule
Open the PDF for A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule in another window
Journal Articles

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies

Jill Gilbert, Sharyn D. Baker, M. Katherine Bowling, Louise Grochow, W. Douglas Figg, Yelena Zabelina, Ross C. Donehower, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2292–2300.
Published: 01 August 2001
View article titled, A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies
Open the PDF for A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies in another window